Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma

Journal of Theoretical Biology

Volumn 265, Issue 3, 2010, Pages 467-480

  Eftimie, Raluca ^a   Bramson, Jonathan L ^b,c   Earn, David J D ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer immunology; CD4+ T cells; Granulocytes; Mathematical modeling; Melanoma

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

CANCER; CELL ORGANELLE; EXPERIMENTAL STUDY; IMMUNITY; NUMERICAL MODEL; TUMOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRANULOCYTE FUNCTION; LEUKOCYTE MIGRATION; MATHEMATICAL MODEL; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIMULATION; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; EOSINOPHIL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; PROCEDURES; SKIN TUMOR;

ANIMALS; COMPUTER SIMULATION; CYTOKINES; EOSINOPHILS; IMMUNOTHERAPY; MELANOMA; MICE; MODELS, IMMUNOLOGICAL; SKIN NEOPLASMS; TH1 CELLS; TH2 CELLS;

MARTES; MUS;

EID: 77954656225     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.04.030     Document Type: Article

References (77)

1. Adam J., Bellomo N. A Survey of Models for Tumor-Immune System Dynamics 1997, Birkhäuser, Boston.
2. Alatrash G., Bukowski R., Tannenbaum C., Finke J. Interleukins. Cancer Chemotherapy and Biotherapy Principles and Practice 2005, 767-809. Lippincott Williams & Wilkins, Philadelphia, (Chapter 36).
3. Algarra I., Cabrera T., Garrido F. The hla crossroad in tumor immunology. Hum. Immunol. 2000, 61(1):65-73.
4. Araujo R., McElwain D. A history of the study of solid tumor growth: the contribution of mathematical modeling. Bull. Math. Biol. 2004, 66:1039-1091.
5. Arciero J., Jackson T., Kirschner D. A mathematical model of tumor-immune evasion and siRNA treatment. Discrete Continuous Dyn. Systems Ser. B 2004, 4(1):39-58.
6. Bajzer Z., Maruĉić M., Vuk-Pavlović S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math. Comput. Modelling 1996, 23(6):31-46.
7. Behrens G., Li M., Smith C., Belz G., Carbone J.M.F., Heath W. Helper t cells, dendritic cells and CTL immunity. Immunol. Cell Biol. 2004, 82(1):84-90.
8. Bellomo N., Bellouquid A., Angelis E.D. The modelling of the immune competition by generalized kinetic (Boltzmann) models: review and research perspectives. Math. Comput. Modelling 2003, 37:65-86.
9. Bellomo N., Delitala M. From the mathematical kinetic, and stochastic game theory to modeling mutations, onset, progression and immune competition of cancer cells. Phys. Life Rev. 2008, 5:183-206.
10. Bellomo N., Li N., Maini P. On the foundations of cancer modeling: selected topics, speculations, and perspectives. Math. Models Methods Appl. Sci. 2008, 18(4):593-646.
11. Bellomo N., Preziosi L. Modelling and mathematical problems related to tumor evolution and its interactions with the immune system. Math. Comput. Modelling 2000, 32:413-452.
12. Brazzoli I., Angelis E.D., Jabin P.-E. A mathematical model of immune competition related to cancer dynamics. Math. Methods Appl. Sci. 2010, 33:733-750.
13. Buonocore S., Surquin M., Moine A.L., Abramowicz D., Flamand V., Goldman M. Amplification of T-cell responses by neutrophils: relevance to allograft immunity. Immunol. Lett. 2004, 94:163-166.
14. Byrne H., Alarcon T., Owen M., Webb S., Maini P. Modeling aspects of cancer dynamics: a review. Philos. Trans. R. Soc. A 2006, 364:1563-1578.
15. 4 mediate the neutrophil migration in immune inflammation. Brit. J. Pharmacol. 2006, 364:1563-1578.
16. Carlo E.D., Forni G., Lolini P., Colombo M., Modesti A., Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001, 97:339-345.
17. Challacombe J., Suhrbier A., Parsons P., Jones B., Hampson P., Kavanagh D., Rainger G.E., Morris M., Lord J., Le T., Hoang-Le D., Ogbourne S.M. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with Ingenol-3-Angelate. J. Immunol. 2006, 177:8123-8132.
18. Chaplain M. Modelling aspects of cancer growth: insight from mathematical and numerical analysis and computational simulation. Multiscale Problems in the Life Sciences. Lecture Notes in Mathematics 2008, vol. 1940/2008:147-200. Springer, Berlin/Heidelberg.
19. Chaplain M., Kuznetsov V., James Z., Stepanova L. Spatio-temporal dynamics of the immune system response to cancer. Mathematical Models in Medical and Health Sciences 1998, 1-20. Vanderbilt University Press, Nashville.
20. Corbin G., Harty J. T cells undergo rapid ON/OFF but not ON/OFF/ON cycling of cytokine production in response to antigen. J. Immunol. 2005, 174:718-726.
21. Cormier S., Taranova A., Bedient C., Nguyen T., Protheroe C., Pero R., Dimina D., Ochkur S., O'Neill K., Colbert D., Lombari T., Constant S., McGarry M., Lee J., Lee N. Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 2006, 79:1131-1139.
22. + T cells. Immunity 2005, 22(3):371-383.
23. Cross A., Moots R., Edwards S. The dual effects of TNF-α on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood 2007, 111(2):878-884.
24. de Pillis L., Gu W., Radunskaya A. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretation. J. Theor. Biol. 2006, 238:841-862.
25. de Pillis L., Radunskaya A., Wiseman C. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 2005, 65(17):7950-7958.
26. Dullens H., Tol M.V.D., de Weger R., Otter W.D. A survey of some formal models in tumor immunology. Cancer Immunol. Immunother. 1986, 23:159-164.
27. Eftimie, R., Bramson, J.L., Earn, D.J.D., 2010. Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull. Math. Biol., doi:10.1007/s11538-010-9526-3.
28. Flynn S., Stockinger B. Tumor and cd4 t cell interactions: tumor escape as a result of reciprocal inactivation. Blood 2003, 101(11):4472-4478.
29. + t cell populations by affecting cell death: insights from modeling CFSE data. J. Immunol. 2007, 179(2):950-957.
30. Garcia-Lorca A., Algarra I., Garrido F. Mhc class i antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 2003, 195(3):346-355.
31. Hamilton D., Bretscher P. The commonality in the regulation of the immune response to most tumors: the prevalence of immune class deviation as a tumor escape mechanism and its significance for vaccination and immunotherapy. Cancer Therapy 2008, 6:745-754.
32. Hamilton D., Bretscher P. Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer. Cancer Immunol. Immunother. 2008, 57:1125-1136.
33. + T cells in the antitumor immune response. J. Exp. Med. 1998, 188:2357-2368.
34. Jeong I., Han K., Joung J., Choi W., Hwang S.-S., Yang S., Seo H., Chung J., Lee K. Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival. J. Korean Med. Sci. 2007, 22(Suppl.):S122-S128.
35. Joshi B., Wang X., Banerjee S., Tian H., Matzavinos A., Chaplain M. On immunotherapies and cancer vaccination protocols: a mathematical modeling approach. J. Theor. Biol. 2009, 259(4):820-827.
36. Kataoka S., Konishi Y., Nishio Y., Fujikawa-Adachi K., Tominaga A. Antitumor activity of eosinophils activated by IL-5 and Eotaxin against hepatocellular carcinoma. DNA Cell Biol. 2004, 23(9):549-560.
37. Kirschner D., Panetta J. Modeling immunotherapy of the tumor-immune interaction. J. Math. Biol. 1998, 37:235-252.
38. Kolev M. Mathematical modeling of the competition between acquired immunity and cancer. Int. J. Math. Comput. Sci. 2003, 13(3):289-296.
39. Kuznetsov V., Makalkin I., Taylor M., Perelson A. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 1994, 2(56):295-321.
40. Lane C., Leitch J., Tan X., Hadjati J., Bramson J., Wan Y. vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 2004, 64(4):1509-1514.
41. Leitch J., Frazer K., Lane C., Putzu K., Adema G., Zhang Q., Jefferies W., Bramson J., Wan Y. Ctl-dependent and independent antitumor immunity is determined by the tumor not the vaccine. J. Immunol. 2004, 172(9):5200-5205.
42. Martins M., S.F., Vilela M. Multiscale models for the growth of avascular tumors. Phys.Life Rev. 2007, 4:128-156.
43. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M., Foster P., Parish C. Immunotherapy of cytotoxic T cell-resistant tumor by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 2003, 197(3):387-393.
44. Matzavinos A., Chaplain M. Travelling-wave analysis of a model of the immune response to cancer. C. R. Biol. 2004, 327(11):995-1008.
45. Matzavinos A., Chaplain M., Kuznetsov V. Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. Math. Med. Biol. 2004, 21(1):1-34.
46. Nagy J. The ecology and evolutionary biology of cancer: a review of mathematical models of necrosis and tumor cells diversity. Math. Biosci. Eng. 2005, 2(2):381-418.
47. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato M., Ohta A. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 1999, 190(5):617-627.
48. Nonaka M., Nonaka R., Woolley K., Adelroth E., Miura K., Okhawara Y., Glibetic M., Nakano K., O'Byrne P., Dolovich J., Jordana M. Distinct immunohistochemical localization of il-4 in human inflamed airway tissues. J. Immunol. 1995, 155:3234-3244.
49. Ohnishi H., Lin K., Chu T. Prolongation of serum half-life of interleukin-2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res. 1990, 50:1107-1112.
50. Ossendorp F., Mengede E., Camps M., Filius R., Melief C. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 1998, 187(5):693-702.
51. Owen M., Sherratt J. Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interactions. J. Theor. Biol. 1997, 189:63-80.
52. Owen M., Sherratt J. Modeling the macrophage invasion of tumors: effects on growth and composition. Math. Med. Biol. 1998, 15:165-185.
53. Owen M., Sherratt J. Mathematical modelling of macrophage dynamics in tumours. Math. Models Methods Appl. Sci. 1999, 9:513-539.
54. Perez-Diez A., Joncker N., Choi K., Chan W., Anderson C., Lantz O., Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354.
55. Poe M., Wu J., Talento A., Koo G. Ctl lysis: there is a hyperbolic relation of killing rate to exocytosable granzyme a for highly cytotoxic murine cytotoxic t lymphocytes. J. Immunol. Methods 1996, 192:37-41.
56. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent of IFN-gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12(6):677-686.
57. Regoes R., Yates A., Antia R. Mathematical model of cytotoxic T-lymphocyte killing. Immunol. Cell Biol. 2007, 85(4):274-279.
58. + T cells depleted?. Proc. Natl. Acad. Sci. 2002, 99:15572-15577.
59. Roose T., Chapman S., Maini P. Mathematical models of avascular tumor growth. SIAM Rev. 2007, 49(2):179-208.
60. Rosenberg S., Lotze M. Cancer immunotherapy using Interleukin-2 and Interleukin-2 activated lymphocytes. Annu. Rev. Immunol. 1986, 4:681-709.
61. Sachs R., Hlatky L., Hahnfeldt P. Simple ODE models of tumor growth and anti-angiogenics or radiataion treatment. Math. Comput. Modelling 2001, 33:1297-1305.
62. Shankaran V., Ikeda H., Bruce A., White J., Swanson P., Old L., Schreiber R. IFN-gamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 2001, 410(6832):1107-1111.
63. Slifka M., Rodriguez F., Whitton J. Rapid on/off cycling of cytokine production by virus-specific cd8textsuperscript+ t cells. Nature 1999, 401:76-79.
64. Smyth M., Godfrey D., Trapani J. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001, 2(4):293-299.
65. Spratt J., von Fournier D., Spratt J., Weber E. Decelerating growth and human breast cancer. Cancer 1993, 71(6):2013-2019.
66. Spry C. Mechanism of eosinophilia. VI. Eosinophil mobilization. Cell. Proliferation 1971, 4:365-374.
67. Szymanska Z. Analysis of immunotherapy models in the context of cancer dynamics. Int. J. Appl. Math. Comput. Sci. 2003, 13:407-418.
68. Tepper R., Coffman R., Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992, 257:548-551.
69. Toes R., Ossendorp F., Offringa R., Melief C. CD4 T cells and their role in atitumor immune responses [comment]. J. Exp. Med. 1999, 189(5):753-756.
70. Tracey K., Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 1994, 45:491-503.
71. van Gisbergen K., Sanchez-Hernandez M., Geijtenbeek T., van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between mac-1 and dc-sign. J. Exp. Med. 2005, 201:1281-1292.
72. Volpert O., Foch T., Koch A., Peterson J., Waltenbaugh C., Tepper R., Bouck N. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 1998, 188(6):1039-1046.
73. Wan Y., Bramson J., Pilon A., Zhu Q., Gauldie J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res. 2000, 60(12):3247-3253.
74. Yamagughi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., Takatsu K., Suda T. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. J. Exp. Med. 1988, 167:1737-1742.
75. Yates A., Bergmann C., van Hemmen J., Stark J., Callard R. Cytokine-modulated regulation of helper T cell population. J. Theor. Biol. 2000, 206:539-560.
76. + T cells: new strategies for cancer vaccine design. J. Immunother. 2001, 24(3):195-204.
77. + T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. Eur. J. Immunol. 2009, 39:1252-1259.